Assays for antimicrobial activity and applications thereof

Patent metadata

Field	Value
Publication number	US-11209432-B2
Application number	US-202016898754-A
Country	US
Kind code	B2
Filing date	Jun 11, 2020
Priority date	Jul 15, 2013
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.

First claim

What is claimed herein is:

1. A method of enhancing microbe detection in a sample by a pattern recognition receptor (PRR)-based assay, the method comprising pre-treating the sample to lyse or kill at least one microbe before assaying with the PRR-based assay to detect the at least one microbe or a microbe-associated molecular pattern (MAMP) thereof, wherein the PRR-based assay comprises detection of the MAMPs using a PRR molecule that is tagged with a detectable label.

2. The method of claim 1 , wherein said pre-treatment is physical, mechanical, chemical, biological, or any combinations thereof.

3. The method of claim 1 , wherein said pre-treatment comprises incubating the sample with an antimicrobial agent.

4. The method of claim 3 , wherein the antimicrobial agent can be selected from aminoglycosides, ansamycins, beta-lactams, bis-biguanides, carbacephems, carbapenems, cationic polypeptides, cephalosporins, fluoroquinolones, glycopeptides, iron-sequestering glycoproteins, linosamides, lipopeptides, macrolides, monobactams, nitrofurans, oxazolidinones, oxazolidinones, penicillins, polypeptides, quaternary ammonium compounds, quinolones, silver compounds, sulfonamides, tetracyclines, and any combinations thereof.

5. The method of claim 1 , wherein said pre-treatment comprises sonication; agitation; vortexing; milling including beadmilling, grinding, french press, cryofracture; and any combinations thereof.

6. The method of claim 1 , wherein said pre-treatment comprises pre-treatment with lysozyme or lysostaphin.

7. The method of claim 1 , wherein said pre-treatment disrupts the architectural integrity of the at least one microbe.

8. The method of claim 1 , wherein said pre-treatment exposes microbe-associated molecular patterns (MAMPs).

9. The method of claim 1 , wherein said pre-treatment increases the sensitivity of the PRR-based assay.

10. The method of claim 1 , wherein said pre-treatment increases the spectrum of microbes that are detected by the PRR-based assay.

11. The method of claim 1 , wherein said at least one microbe has a masking capsule.

12. The method of claim 1 , wherein said at least one microbe is non-capsulated.

13. The method of claim 1 , wherein said at least one microbe is selected from the genus of Acineobacter, Aeromonas, Burkholderia, Candida, Citrobacter, Enterobacter, Enterococcus, Escherichia, Klebsiella, Morganella, Mycobacterium, Proteus, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Staphylococcus, Stenotrophomonas, Streptococcus, Yersinia , or any combinations thereof.

14. The method of claim 1 , wherein said at least one microbe is resistant to at least one antimicrobial agent.

15. The method of claim 1 , wherein the PRR-based assay comprises binding of the MAMPs to a PRR-tethered surface or a PRR-coated solid substrate surface.

16. The method of claim 15 , wherein the surface or solid substrate surface is a surface of a bead; a particle; a microparticle; a nanoparticle; a hollow fiber; a fiber; a porous solid substrate; a filter; a screen; a mesh; a tube; a scaffold; a plate; a channel; a gold particle; a magnetic material; a medical apparatus; a needle; a catheter; an implant; a dipstick; a test strip; a filtration device; a membrane; a hollow fiber cartridge; a microfluidic device; a mixing element; a spiral mixer; an extracorporeal device; or any combinations thereof.

17. The method of claim 15 , wherein the PRR-based assay comprises detection of the MAMPs using a PRR molecule and the PRR molecule is the same molecule as tethered to the surface or coated onto the solid substrate surface.

18. The method of claim 15 , wherein the PRR-based assay comprises detection of the MAMPs using a PRR molecule and the PRR molecule is different from the PRR molecule tethered to the surface or coated onto the solid substrate surface.

19. The method of claim 1 , wherein the PRR-based assay is Fc-mannose-binding lectin (FcMBL) based microbe capture and detection assay.

Assignees

• Harvard College

Inventors

• Cartwright Mark J
• Gamini Nazita
• Ingber Donald E
• Rottman Martin
• Super Michael
• Tomolonis Julie A
• Sinclair Karen A

Classifications

• G01N2333/4724

  Lectins · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N33/5695

  Mycobacteria · CPC title

• C12Q1/18

  Testing for antimicrobial activity of a material · CPC title

• G01N33/56916

  Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia · CPC title